Corporation
McKesson Canada
- Meetings this Parliament
- 24
- With MPs
- 9
- Since Nov 2021
- 45
- Active registrations
- 1
Most recent reported meeting: Aug 4, 2026.
Lobbying by McKesson Canada: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Feb 2, 2026
Filed by Dimitris Polygenis, President
Lobbyists
- Anthony Leong · Vice President, Public Policy & Government Affairs
- David Veillette · Vice President, Government Affairs QC & Atlantic Canada
- Jharna Bajaj · Sr Mgr, Government Relations
Institutions they may lobby: Competition Bureau Canada (COBU), Employment and Social Development Canada (ESDC), Environment and Climate Change Canada (ECCC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Justice Canada (JC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Safety Canada (PS), Public Services and Procurement Canada (PSPC), Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (11)Hide details
- How AI, automation, and healthcare data interoperability can support patient care throughout the healthcare system, particularly in the pharmacy and pharmaceutical distribution sectors
- Policies and programs aimed at red tape reduction to reduce regulatory burdens and timelines in the pharmaceutical distribution and associated sectors
- Offer recommendations on the Patented Medicines Pricing Review Board excessive pricing policy guidelines and implementation approaches to support drug supply stability and system sustainability
- Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs
- Medical cannabis policy impacts on pharmacy and the wholesale industry
- Health Canada, with respect to the role of wholesalers in the management of drug shortages
- Health Canada, with respect to the regulation and funding of wholesale distribution of pharmaceuticals and regulation of pharmacy activities
- Health Canada, with respect to pandemic planning, particularly federal/provincial/territorial storage and distribution of pharmaceuticals
- Development of screening programs in First Nations communities
- Approaches towards National Pharmacare policy
- Approaches to mitigating the impact of COVID-19 on the pharmaceutical distribution, pharmacy, primary care, and other healthcare sectors
Registration 962320-263742-42. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Joan Eliasek (29), Dimitris Polygenis (15), Rebecca McKillican (1).
-
Reported by Dimitris Polygenis · In-house (corporation)
- Raquel Dancho · Member of Parliament
Health Canada, with respect to the role of wholesalers in the management of drug shortages Read more
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs
Health Canada, with respect to the regulation and funding of wholesale distribution of pharmaceuticals and regulation of pharmacy activities
-
Reported by Dimitris Polygenis · In-house (corporation)
- Rechie Valdez · Member of Parliament
Health Canada, with respect to the regulation and funding of wholesale distribution of pharmaceuticals and regulation of pharmacy activities Read more
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs
-
Reported by Dimitris Polygenis · In-house (corporation)
- Aaron Wudrick · Director of Policy, House of Commons
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs Read more
Health Canada, with respect to the regulation and funding of wholesale distribution of pharmaceuticals and regulation of pharmacy activities
-
Reported by Dimitris Polygenis · In-house (corporation)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Health Canada, with respect to the regulation and funding of wholesale distribution of pharmaceuticals and regulation of pharmacy activities Read more
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs
-
Reported by Dimitris Polygenis · In-house (corporation)
- Ali Ehsaasi · MP Willowdale, House of Commons
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs Read more
Health Canada, with respect to the regulation and funding of wholesale distribution of pharmaceuticals and regulation of pharmacy activities
-
Reported by Dimitris Polygenis · In-house (corporation)
- Anthony Laporte · Strategic Advisor, Implementation and Delivery, Prime Minister's Office (PMO)
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs Read more
Health Canada, with respect to the regulation and funding of wholesale distribution of pharmaceuticals and regulation of pharmacy activities
-
Reported by Dimitris Polygenis · In-house (corporation)
- Elizabeth Wong · Sr Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs Read more
Health Canada, with respect to the regulation and funding of wholesale distribution of pharmaceuticals and regulation of pharmacy activities
-
Reported by Dimitris Polygenis · In-house (corporation)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs Read more
Health Canada, with respect to the regulation and funding of wholesale distribution of pharmaceuticals and regulation of pharmacy activities
-
Reported by Dimitris Polygenis · In-house (corporation)
- Jade Mallette · Chief of Staff, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Health Canada, with respect to the regulation and funding of wholesale distribution of pharmaceuticals and regulation of pharmacy activities Read more
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs
-
Reported by Dimitris Polygenis · In-house (corporation)
- Paul Morin · Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Health Canada, with respect to the regulation and funding of wholesale distribution of pharmaceuticals and regulation of pharmacy activities Read more
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs
-
Reported by Dimitris Polygenis · In-house (corporation)
- Pamela Aung-Thin · ADM, HPFB, Health Canada (HC)
Policies and programs aimed at red tape reduction to reduce regulatory burdens and timelines in the pharmaceutical distribution and associated sectors
-
Reported by Dimitris Polygenis · In-house (corporation)
- Maggie Chi · MP Don Valley North
Health Canada, with respect to the regulation and funding of wholesale distribution of pharmaceuticals and regulation of pharmacy activities
-
Reported by Dimitris Polygenis · In-house (corporation)
- Rechie Valdez · Member of Parliament
Health Canada, with respect to the regulation and funding of wholesale distribution of pharmaceuticals and regulation of pharmacy activities
-
Reported by Dimitris Polygenis · In-house (corporation)
- Maninder Sidhu · Minister of International Trade, Global Affairs Canada (GAC)
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs
-
Reported by Dimitris Polygenis · In-house (corporation)
- Kristina Tesser Derksen · MP Milton
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs Read more
Health Canada, with respect to the regulation and funding of wholesale distribution of pharmaceuticals and regulation of pharmacy activities
-
Reported by Joan Eliasek · In-house (corporation)
- Marjorie Michel · Minister of Health, Health Canada (HC)
Approaches towards National Pharmacare policy Read more
Health Canada, with respect to the role of wholesalers in the management of drug shortages
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs
-
Reported by Joan Eliasek · In-house (corporation)
- Ernie Klassen · MP South Surrey Whiterock
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs
-
Reported by Joan Eliasek · In-house (corporation)
- Guillaume Couillard · Director General, Patented Medicine Prices Review Board (PMPRB)
Offer recommendations on the Patented Medicines Pricing Review Board excessive pricing policy guidelines and implementation approaches to support drug supply stability and system sustainability Read more
-
Reported by Joan Eliasek · In-house (corporation)
- Neeraj Bhalla · Director Stakeholder Relations, Global Affairs Canada (GAC)
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs
-
Reported by Joan Eliasek · In-house (corporation)
- Galen Richardson · Senior Policy Advisor Stakeholder Relations, Privy Council Office (PCO)
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs
-
Reported by Joan Eliasek · In-house (corporation)
- Anie Perrault · Acting Chairperson, Patented Medicine Prices Review Board (PMPRB)
Offer recommendations on the Patented Medicines Pricing Review Board excessive pricing policy guidelines and implementation approaches to support drug supply stability and system sustainability Read more
-
Reported by Joan Eliasek · In-house (corporation)
- Chris Malette · MP Bay of Quinte
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs
-
Reported by Joan Eliasek · In-house (corporation)
- Jibril Hussein · Intern, Innovation, Science and Economic Development Canada (ISED)
- Sandenga Yeba · Senior Policy Advisor to the Minister, Health Canada (HC)
- Bryn Savage · Policy Advisor, Health Canada (HC)
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs
-
Reported by Joan Eliasek · In-house (corporation)
- Sean Burgess · Communications Consultant, Health Canada (HC)
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs
-
Reported by Joan Eliasek · In-house (corporation)
- Eshan Naik · Dir Policy & Health Policy, Health Canada (HC)
Discuss policy measures to protect Canada's drug supply, distribution, and pharmacy systems against the impact of US tariffs
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.